Nplate (romiplostim) out-of-pocket (OOP) costs
72% of Nplate® claims have $0 out-of-pocket costs for the patient*

Patients have access to support regardless of type of coverage, including Amgen Assist 360™, Amgen FIRST STEP™, and the Amgen Safety Net Foundation.

See How We Can Help Your Patients

Amgen Assist 360™ and Nplate® Navigator are here to offer the tools, information, and support for Amgen products that make a difference for you and your patients.

Learn more below, or contact Amgen Assist 360™ at 1‑888‑4ASSIST1‑888‑4ASSIST or visit AmgenAssist360.com for more information.

*Data based on IMS Remit Data for 1/1 /2016-12/31 /2017 for all payors, including commercial and government. Claims included in this analysis were categorized according to patient out-of-pocket costs for Nplate®. The majority of patients who do have out-of-pocket costs pay between $0 and $300 dollars.11

Patient access and reimbursement
Patient support

Amgen Assist 360™:
Introducing support, simplified

Amgen Reimbursement Specialists
  • Connect with an Amgen Reimbursement Counselor or schedule a visit with a Field Reimbursement Specialist
Patient Resource Guide
  • Find co-pay and reimbursement resources for patients with different kinds of insurance or no insurance at all
Benefit Verification
  • Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product

To learn more, please visit www.AmgenAssist360.com.

Nplate® FIRST STEP™ program

The Nplate® FIRST STEP™ program can help your eligible commerically insured patients reduce out-of-pocket costs for Nplate®.

To enroll your practice in the Nplate®  FIRST STEP™ program, please call 1-888-65-STEP11-888-65-STEP1 (1-888-657-83711-888-657-8371).

This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE®, or where otherwise prohibited by law.

The Amgen Safety Net Foundation

Based on income, uninsured patients may qualify for support from the Amgen Safety Net Foundation.

  • The Amgen Safety Net Foundation provides Amgen products at no cost to qualifying patients.
  • Patients may qualify if they have no or limited drug coverage and meet income eligibility requirements.
  • Patient must be a US resident to qualify.

For more information, please contact the Amgen Safety Net Foundation at 1-888-762-64361-888-762-6436 or visit AmgenSafetyNetFoundation.com.

Learn about Nplate® Navigator Patient Support

Nplate® Navigator patient support program

Nplate® Navigator may help:

  • Answer questions about adult chronic immune thrombocytopenia (ITP) and Nplate® by allowing your patients to speak with a nurse*
  • Provide information about finding resources that may be able to help your patients afford their medication
  • Identify a list of local ITP specialists while patients are traveling or relocating domestically
  • Keep patients informed with educational e-mails and direct mailings

*The Nplate® Navigator program and its nurses are not intended to provide medical advice, diagnose health problems, or take the place of speaking with a healthcare professional about a patient’s condition, treatment, or medication.

Patients can call Nplate® Navigator toll-free at 1‑855‑7Nplate1‑855‑7Nplate (1‑855‑767‑52831‑855‑767‑5283) Monday through Friday, 9:00 AM–9:00 PM ET or sign up online.

Learn about patient access and reimbursement

Important Safety Information

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

  • Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
  • To detect antibody formation, submit blood samples to Amgen (1‑800‑772‑64361‑800‑772‑6436). Amgen will assay these samples for antibodies to Nplate® and thrombopoietin (TPO).
  • Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.

Adverse Reactions

Adult ITP

  • In the placebo-controlled trials of adult ITP patients, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Headaches were usually of mild or moderate severity.
  • Most common adverse reactions in adults (≥ 5% higher patient incidence in Nplate® versus placebo) were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).

Pediatric ITP

  • In pediatric patients of age ≥ 1 year receiving romiplostim for ITP, adverse reactions with an incidence of ≥ 25% in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).
  • Most common adverse reactions (≥ 5% incidence and ≥ 5% more frequent in the romiplostim arm) across the two placebo-controlled trials were contusion (41%), upper respiratory tract infection (31%), oropharyngeal pain (25%), pyrexia (24%), diarrhea (20%), rash (15%), and upper abdominal pain (14%).

Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

Women who become pregnant during Nplate® treatment are encouraged to enroll in Amgen's Pregnancy Surveillance Program. Patients or their physicians should call 1‑800‑77‑AMGEN1‑800‑77‑AMGEN (1‑800‑772‑64361‑800‑772‑6436) to enroll.

INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

Please see full Prescribing Information and Medication Guide.

See More Close

Important Safety Information

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

  • Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
  • To detect antibody formation, submit blood samples to Amgen (1‑800‑772‑64361‑800‑772‑6436). Amgen will assay these samples for antibodies to Nplate® and thrombopoietin (TPO).
  • Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.

Adverse Reactions

Adult ITP

  • In the placebo-controlled trials of adult ITP patients, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Headaches were usually of mild or moderate severity.
  • Most common adverse reactions in adults (≥ 5% higher patient incidence in Nplate® versus placebo) were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).

Pediatric ITP

  • In pediatric patients of age ≥ 1 year receiving romiplostim for ITP, adverse reactions with an incidence of ≥ 25% in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).
  • Most common adverse reactions (≥ 5% incidence and ≥ 5% more frequent in the romiplostim arm) across the two placebo-controlled trials were contusion (41%), upper respiratory tract infection (31%), oropharyngeal pain (25%), pyrexia (24%), diarrhea (20%), rash (15%), and upper abdominal pain (14%).

Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

Women who become pregnant during Nplate® treatment are encouraged to enroll in Amgen's Pregnancy Surveillance Program. Patients or their physicians should call 1‑800‑77‑AMGEN1‑800‑77‑AMGEN (1‑800‑772‑64361‑800‑772‑6436) to enroll.

INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

Please see full Prescribing Information and Medication Guide.

Reference: 1. Data on file, Amgen.

Back to top

You are now leaving NplateHCP.com


Please be aware that sponsors of this site are not responsible for content on the site you are about to enter

Return to previous page Continue to external site